Komori
Human Metabolome Technologies (6090) · InitiativeFirst stated

Strengthening technological competitiveness in ultra-high-sensitivity and multi-omics technologies

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Strengthening the Drug Discovery Platform through the Introduction of New Technologies and Research PlatformsA theme 5 companies write about · 0 as a headwind · 5 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「Highly sensitive analysis will be substantially upgraded to “ultra-high-sensitivity analysis,” and we will also seek to further shorten turnaround times through higher throughput. We will also work to develop multi-omics analysis technologies compatible with DIA, a data-driven analysis method, and library-free annotation technology that can identify substances without using reference-standard reagents.」

    For the digital biology era, ultra-high-sensitivity analysis, higher throughput, DIA-compatible multi-omics and library-free annotation were identified as new priority initiatives for development.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening technological competitiveness in ultra-high-sensitivity and multi-omics technologies | Human Metabolome Technologies,Inc. (6090) | Komori